Medical University Of South Carolina (MUSC)
Welcome,         Profile    Billing    Logout  
 103 Trials 
402 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rockey, Don
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
Kraveka, Jacqueline
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
George, Mark S
NCT06462820: SAINT for MDD in an Inpatient Setting Follow-on

Not yet recruiting
2/3
100
US
Active SAINT Stimulation, Sham SAINT Stimulation
Magnus Medical
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
12/25
02/26
NCT03693105: The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

Not yet recruiting
2/3
100
US
Active SAINT Stimulation, Sham SAINT Stimulation
Magnus Medical, National Institute of Mental Health (NIMH)
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
12/25
02/26
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Active, not recruiting
N/A
160
US, RoW
Relivion®DP- Active, Relivion®DP- Sham
Neurolief Ltd.
MDD
06/24
06/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Not yet recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Bruzzese, Jean-Marie
NCT05091034: CAMP Air: Efficacy and Cost-effectiveness in Urban Adolescents

Enrolling by invitation
N/A
740
US
Controlling Asthma Program for Adolescents (CAMP Air), CAMP Air, Attention Control Asthma Education Intervention, Asthma Plus
Columbia University, 3-C Institute for Social Development, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
06/26
12/26
Wagner, Carol L
NCT03978000 / 2018-000754-22: IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Active, not recruiting
3
2158
Europe, US, RoW
IBP-9414, Placebo
Infant Bacterial Therapeutics
Necrotizing Enterocolitis
06/24
07/24
Strange, Charlie
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT04722887: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Recruiting
1/2
16
US
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human), Prolastin®-C Liquid
Grifols Therapeutics LLC
Alpha1-Antitrypsin Deficiency
03/25
03/25
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients With COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
09/24
09/28
Litwin, Sheldon E
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Active, not recruiting
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
06/24
07/24
Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting
N/A
80
US
Satera GSN Ablation, Sham Control
Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction
04/22
03/23
Shapiro, Amy
NCT04567511: Hemlibra in Mild Hemophilia A

Recruiting
4
20
US
Emicizumab, Hemlibra
Indiana Hemophilia &Thrombosis Center, Inc., Genentech, Inc.
Factor VIII Deficiency, Congenital
07/25
07/27
The Atlanta Study, NCT04030052: Emicizumab PUPs and Nuwiq ITI Study

Withdrawn
3
2
US
Nuwiq (low dose protocol), Simoctocog alfa, HEMLIBRA, Emicizumab, ACE910, and RO5534262, Nuwiq (Atlanta protocol)
Emory University, Genentech, Inc.
Hemophilia A
01/23
01/23
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Recruiting
3
71
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications

Active, not recruiting
N/A
550
US
Standard care with blood and urine sample collection
Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
Factor IX Deficiency
06/19
12/21
NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed
N/A
86
US
American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical
Hemophilia A and B, Liver Transplantation
12/22
12/22
NCT03853486: ATHN 9: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Uhde, Thomas W
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences, LLC
Idiopathic Hypersomnia
08/23
08/23
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
NCT05668754: Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Active, not recruiting
2
48
US
Serdexmethylphenidate, SDX, Placebo
Zevra Therapeutics, Rho, Inc.
Idiopathic Hypersomnia
06/24
06/24
Romano, Matthew
ReChord, NCT02803957: Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair

Recruiting
N/A
585
US
NeoChord DS1000, Surgical Mitral Valve Repair
NeoChord
Mitral Valve Insufficiency
07/22
07/27
NCT05089877: FREEZE-AFIB Post-Market Study

Active, not recruiting
N/A
39
US
Surgical Ablation
AtriCure, Inc.
Atrial Fibrillation, Atrial Flutter
03/23
08/23
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
06/24
06/28
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
12/26
MOMENTIS, NCT05526560: Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Active, not recruiting
N/A
500
Canada, US
MITRIS RESILIA Mitral Valve, Model 11400M
Edwards Lifesciences
Mitral Stenosis, Mitral Valve Insufficiency
01/28
12/35
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Atz, Andrew
FUEL-2, NCT05918211: Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Recruiting
3
436
US
Udenafil, Placebo
Mezzion Pharma Co. Ltd
Single Ventricle Heart Disease
10/25
10/25
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Turner, Raymond S
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
06/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US, RoW
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting
3
750
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Recruiting
3
600
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
10/25
10/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
05/29
NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
MIRROR, NCT04494295: The Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

Recruiting
N/A
500
US
Aurora Surgiscope System
Integra LifeSciences Corporation, Icahn School of Medicine at Mount Sinai, Oculus Imaging LLC
Supratentorial Hemorrhage
10/28
10/29
Giordano, Sara
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
Flume, Patrick
NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Withdrawn
2
80
US
Sodium Fusidate, ACG-701, ARV-1801, Placebo
Aceragen
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
09/23
09/23
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
01/24
03/24
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Recruiting
2
60
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
PTK0796-NTM-20203, NCT04922554: Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Active, not recruiting
2
75
US
Omadacycline Oral Tablet, Nuzyra, Placebo, placebo tablets
Paratek Pharmaceuticals Inc
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
06/24
07/24
NCT05010577: Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Active, not recruiting
1b/2a
32
Europe, US, RoW
BX004-A, Bacteriophage, Placebo, Vehicle buffer
BiomX, Inc.
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
10/23
03/24
Huggins, John
PREDICT, NCT03448926: The Registry for DCIS Patients With DCISionRT Testing

Suspended
N/A
2500
US, RoW
Treatment Recommendation Surveys
PreludeDx, University of South Florida
DCIS
11/25
11/35
Savage, Stephen
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
Strange, Charlton B
Serpentine-1, NCT06049082: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Recruiting
1
12
US
KB408 (Nebulization)
Krystal Biotech, Inc.
Alpha 1-Antitrypsin Deficiency
06/25
05/26
SPRAY-CB, NCT03893370: RejuvenAir® System Trial for COPD With Chronic Bronchitis

Active, not recruiting
N/A
210
Europe, US
RejuvenAir System, Sham Control Procedure
CSA Medical, Inc.
Chronic Bronchitis
05/25
09/26
D'Alessandro, David
BTR EFS, NCT05291884: Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study

Recruiting
N/A
10
US
Impella BTR
Abiomed Inc.
Heart Failure, Acute Decompensated Heart Failure
10/23
01/24
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
12/24
12/24
IMPACT, NCT05529654: IMpella-Protected cArdiaC Surgery Trial

Enrolling by invitation
N/A
100
US
Impella 5.5 with SmartAssist
Abiomed Inc.
Left Ventricular Dysfunction
09/24
09/25
NCT05047068: OCS Heart Perfusion Post-Approval Registry

Active, not recruiting
N/A
350
US
OCS Heart System
TransMedics
Transplant
12/25
12/29
OHP-II, NCT05915299: Sponsor-Initiated OCS Heart Perfusion Registry

Recruiting
N/A
5000
US
OCS Heart
TransMedics
Heart Transplant
08/29
08/33
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Thomas, Wendy
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
12/24
12/24
Veeraswamy, Ravi
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
08/24
10/29
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
19
US
Oxybutynin, Gelnique
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Recruiting
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
12/24
04/25
NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Recruiting
4
336
Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
03/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Recruiting
4
200
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
09/24
10/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT04994535: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
Allergan
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Active, not recruiting
3
1321
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin single dose, Dalbavancin two dose, Comparator
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
12/23
12/23
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Active, not recruiting
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1080
Europe, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
05/37
05/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Calendar Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Calendar Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Active, not recruiting
3
429
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
03/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Active, not recruiting
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
08/24
08/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting
3
880
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Dupilumab
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
07/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Calendar Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
09/27
09/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
US
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/25
03/26
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
US
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Active, not recruiting
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Calendar Jan 2024 - Dec 2024: Submission for r/r myelofibrosis in combination with Jakafi (based on TRANSFORM-2 trial)
Calendar Jan 2024 - Dec 2024: Data readout from TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Active, not recruiting
3
295
Europe, Canada, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
11/24
01/25
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide 72 μg (FC Participants), Placebo (FC Participants), Linaclotide 145 μg (IBS-C Participants), Linaclotide 290 μg (IBS-C Participants)
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Active, not recruiting
3
132
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
12/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Recruiting
3
152
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
11/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Recruiting
3
116
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
08/25
11/25
NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
12/24
06/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Recruiting
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
12/24
04/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Active, not recruiting
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
10/24
10/24
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Active, not recruiting
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Recruiting
3
1500
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
05/25
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
06/25
03/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Recruiting
3
156
Europe, Canada
ELAPR002f Injectable Gel, Saline Control
AbbVie
Atrophic Acne Scars
08/25
08/25
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Recruiting
3
280
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting
3
480
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
09/25
08/26
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
3
1328
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa
11/25
08/27
 

Download Options